 | • レポートコード：GIR-23F3897 • 出版社/出版日：GlobalInfoResearch / 2023年2月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、78ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Poliovirus Vaccine Inactivated Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界の不活化ポリオウイルスワクチンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 不活化ポリオウイルスワクチン市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・ヒト二倍体細胞、サル腎細胞 アプリケーション別セグメントは次のように区分されます。 ・公用、民間用 世界の不活化ポリオウイルスワクチン市場の主要なマーケットプレーヤーは以下のとおりです。 ・Sanofi、GSK、Serum Institute (Bilthoven Biologicals)、IMBCA 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - 不活化ポリオウイルスワクチンの概要 - タイプ別分析（2017年vs2021年vs2028年）：ヒト二倍体細胞、サル腎細胞 - アプリケーション別分析（2017年vs2021年vs2028年）：公用、民間用 - 世界の不活化ポリオウイルスワクチン市場規模・予測 - 世界の不活化ポリオウイルスワクチン生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Sanofi、GSK、Serum Institute (Bilthoven Biologicals)、IMBCA ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：ヒト二倍体細胞、サル腎細胞 ・アプリケーション別分析2017年-2028年：公用、民間用 ・不活化ポリオウイルスワクチンの北米市場分析 - 不活化ポリオウイルスワクチンの北米市場：タイプ別市場規模2017年-2028年 - 不活化ポリオウイルスワクチンの北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・不活化ポリオウイルスワクチンのヨーロッパ市場分析 - ：不活化ポリオウイルスワクチンのヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：不活化ポリオウイルスワクチンのヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・不活化ポリオウイルスワクチンのアジア太平洋市場分析 - 不活化ポリオウイルスワクチンのアジア太平洋市場：タイプ別市場規模2017年-2028年 - 不活化ポリオウイルスワクチンのアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・不活化ポリオウイルスワクチンの南米市場分析 - 不活化ポリオウイルスワクチンの南米市場：タイプ別市場規模2017年-2028年 - 不活化ポリオウイルスワクチンの南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・不活化ポリオウイルスワクチンの中東・アフリカ市場分析 - 不活化ポリオウイルスワクチンの中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 不活化ポリオウイルスワクチンの中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Poliovirus Vaccine Inactivated market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Poliovirus Vaccine Inactivated market size is estimated to be worth US$ 730.3 million in 2021 and is forecast to a readjusted size of USD 957.4 million by 2028 with a CAGR of 3.9% during review period. Public accounting for % of the Poliovirus Vaccine Inactivated global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Human Diploid Cell segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Poliovirus Vaccine Inactivated include Sanofi, GSK, Serum Institute (Bilthoven Biologicals), IMBCA, and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Poliovirus Vaccine Inactivated market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Human Diploid Cell
Monkey Kidney Cell
Market segment by Application can be divided into
Public
Private
The key market players for global Poliovirus Vaccine Inactivated market are listed below:
Sanofi
GSK
Serum Institute (Bilthoven Biologicals)
IMBCA
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Poliovirus Vaccine Inactivated product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Poliovirus Vaccine Inactivated, with price, sales, revenue and global market share of Poliovirus Vaccine Inactivated from 2019 to 2022.
Chapter 3, the Poliovirus Vaccine Inactivated competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Poliovirus Vaccine Inactivated breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Poliovirus Vaccine Inactivated market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Poliovirus Vaccine Inactivated.
Chapter 13, 14, and 15, to describe Poliovirus Vaccine Inactivated sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Poliovirus Vaccine Inactivated Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Poliovirus Vaccine Inactivated Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Human Diploid Cell
1.2.3 Monkey Kidney Cell
1.3 Market Analysis by Application
1.3.1 Overview: Global Poliovirus Vaccine Inactivated Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Public
1.3.3 Private
1.4 Global Poliovirus Vaccine Inactivated Market Size & Forecast
1.4.1 Global Poliovirus Vaccine Inactivated Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Poliovirus Vaccine Inactivated Sales in Volume (2017-2028)
1.4.3 Global Poliovirus Vaccine Inactivated Price (2017-2028)
1.5 Global Poliovirus Vaccine Inactivated Production Capacity Analysis
1.5.1 Global Poliovirus Vaccine Inactivated Total Production Capacity (2017-2028)
1.5.2 Global Poliovirus Vaccine Inactivated Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Poliovirus Vaccine Inactivated Market Drivers
1.6.2 Poliovirus Vaccine Inactivated Market Restraints
1.6.3 Poliovirus Vaccine Inactivated Trends Analysis
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Poliovirus Vaccine Inactivated Product and Services
2.1.4 Sanofi Poliovirus Vaccine Inactivated Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK Poliovirus Vaccine Inactivated Product and Services
2.2.4 GSK Poliovirus Vaccine Inactivated Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Serum Institute (Bilthoven Biologicals)
2.3.1 Serum Institute (Bilthoven Biologicals) Details
2.3.2 Serum Institute (Bilthoven Biologicals) Major Business
2.3.3 Serum Institute (Bilthoven Biologicals) Poliovirus Vaccine Inactivated Product and Services
2.3.4 Serum Institute (Bilthoven Biologicals) Poliovirus Vaccine Inactivated Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 IMBCA
2.4.1 IMBCA Details
2.4.2 IMBCA Major Business
2.4.3 IMBCA Poliovirus Vaccine Inactivated Product and Services
2.4.4 IMBCA Poliovirus Vaccine Inactivated Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Poliovirus Vaccine Inactivated Breakdown Data by Manufacturer
3.1 Global Poliovirus Vaccine Inactivated Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Poliovirus Vaccine Inactivated Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Poliovirus Vaccine Inactivated
3.4 Market Concentration Rate
3.4.1 Top 3 Poliovirus Vaccine Inactivated Manufacturer Market Share in 2021
3.4.2 Top 6 Poliovirus Vaccine Inactivated Manufacturer Market Share in 2021
3.5 Global Poliovirus Vaccine Inactivated Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Poliovirus Vaccine Inactivated Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Poliovirus Vaccine Inactivated Market Size by Region
4.1.1 Global Poliovirus Vaccine Inactivated Sales in Volume by Region (2017-2028)
4.1.2 Global Poliovirus Vaccine Inactivated Revenue by Region (2017-2028)
4.2 North America Poliovirus Vaccine Inactivated Revenue (2017-2028)
4.3 Europe Poliovirus Vaccine Inactivated Revenue (2017-2028)
4.4 Asia-Pacific Poliovirus Vaccine Inactivated Revenue (2017-2028)
4.5 South America Poliovirus Vaccine Inactivated Revenue (2017-2028)
4.6 Middle East and Africa Poliovirus Vaccine Inactivated Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Poliovirus Vaccine Inactivated Sales in Volume by Type (2017-2028)
5.2 Global Poliovirus Vaccine Inactivated Revenue by Type (2017-2028)
5.3 Global Poliovirus Vaccine Inactivated Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Poliovirus Vaccine Inactivated Sales in Volume by Application (2017-2028)
6.2 Global Poliovirus Vaccine Inactivated Revenue by Application (2017-2028)
6.3 Global Poliovirus Vaccine Inactivated Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Poliovirus Vaccine Inactivated Sales by Type (2017-2028)
7.2 North America Poliovirus Vaccine Inactivated Sales by Application (2017-2028)
7.3 North America Poliovirus Vaccine Inactivated Market Size by Country
7.3.1 North America Poliovirus Vaccine Inactivated Sales in Volume by Country (2017-2028)
7.3.2 North America Poliovirus Vaccine Inactivated Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Poliovirus Vaccine Inactivated Sales by Type (2017-2028)
8.2 Europe Poliovirus Vaccine Inactivated Sales by Application (2017-2028)
8.3 Europe Poliovirus Vaccine Inactivated Market Size by Country
8.3.1 Europe Poliovirus Vaccine Inactivated Sales in Volume by Country (2017-2028)
8.3.2 Europe Poliovirus Vaccine Inactivated Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Poliovirus Vaccine Inactivated Sales by Type (2017-2028)
9.2 Asia-Pacific Poliovirus Vaccine Inactivated Sales by Application (2017-2028)
9.3 Asia-Pacific Poliovirus Vaccine Inactivated Market Size by Region
9.3.1 Asia-Pacific Poliovirus Vaccine Inactivated Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Poliovirus Vaccine Inactivated Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Poliovirus Vaccine Inactivated Sales by Type (2017-2028)
10.2 South America Poliovirus Vaccine Inactivated Sales by Application (2017-2028)
10.3 South America Poliovirus Vaccine Inactivated Market Size by Country
10.3.1 South America Poliovirus Vaccine Inactivated Sales in Volume by Country (2017-2028)
10.3.2 South America Poliovirus Vaccine Inactivated Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Poliovirus Vaccine Inactivated Sales by Type (2017-2028)
11.2 Middle East & Africa Poliovirus Vaccine Inactivated Sales by Application (2017-2028)
11.3 Middle East & Africa Poliovirus Vaccine Inactivated Market Size by Country
11.3.1 Middle East & Africa Poliovirus Vaccine Inactivated Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Poliovirus Vaccine Inactivated Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Poliovirus Vaccine Inactivated and Key Manufacturers
12.2 Manufacturing Costs Percentage of Poliovirus Vaccine Inactivated
12.3 Poliovirus Vaccine Inactivated Production Process
12.4 Poliovirus Vaccine Inactivated Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Poliovirus Vaccine Inactivated Typical Distributors
13.3 Poliovirus Vaccine Inactivated Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Poliovirus Vaccine Inactivated Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Poliovirus Vaccine Inactivated Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Sanofi Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Major Business
Table 5. Sanofi Poliovirus Vaccine Inactivated Product and Services
Table 6. Sanofi Poliovirus Vaccine Inactivated Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. GSK Basic Information, Manufacturing Base and Competitors
Table 8. GSK Major Business
Table 9. GSK Poliovirus Vaccine Inactivated Product and Services
Table 10. GSK Poliovirus Vaccine Inactivated Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Serum Institute (Bilthoven Biologicals) Basic Information, Manufacturing Base and Competitors
Table 12. Serum Institute (Bilthoven Biologicals) Major Business
Table 13. Serum Institute (Bilthoven Biologicals) Poliovirus Vaccine Inactivated Product and Services
Table 14. Serum Institute (Bilthoven Biologicals) Poliovirus Vaccine Inactivated Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. IMBCA Basic Information, Manufacturing Base and Competitors
Table 16. IMBCA Major Business
Table 17. IMBCA Poliovirus Vaccine Inactivated Product and Services
Table 18. IMBCA Poliovirus Vaccine Inactivated Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Global Poliovirus Vaccine Inactivated Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 20. Global Poliovirus Vaccine Inactivated Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 21. Market Position of Manufacturers in Poliovirus Vaccine Inactivated, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 22. Global Poliovirus Vaccine Inactivated Production Capacity by Company, (K Units): 2020 VS 2021
Table 23. Head Office and Poliovirus Vaccine Inactivated Production Site of Key Manufacturer
Table 24. Poliovirus Vaccine Inactivated New Entrant and Capacity Expansion Plans
Table 25. Poliovirus Vaccine Inactivated Mergers & Acquisitions in the Past Five Years
Table 26. Global Poliovirus Vaccine Inactivated Sales by Region (2017-2022) & (K Units)
Table 27. Global Poliovirus Vaccine Inactivated Sales by Region (2023-2028) & (K Units)
Table 28. Global Poliovirus Vaccine Inactivated Revenue by Region (2017-2022) & (USD Million)
Table 29. Global Poliovirus Vaccine Inactivated Revenue by Region (2023-2028) & (USD Million)
Table 30. Global Poliovirus Vaccine Inactivated Sales by Type (2017-2022) & (K Units)
Table 31. Global Poliovirus Vaccine Inactivated Sales by Type (2023-2028) & (K Units)
Table 32. Global Poliovirus Vaccine Inactivated Revenue by Type (2017-2022) & (USD Million)
Table 33. Global Poliovirus Vaccine Inactivated Revenue by Type (2023-2028) & (USD Million)
Table 34. Global Poliovirus Vaccine Inactivated Price by Type (2017-2022) & (USD/Unit)
Table 35. Global Poliovirus Vaccine Inactivated Price by Type (2023-2028) & (USD/Unit)
Table 36. Global Poliovirus Vaccine Inactivated Sales by Application (2017-2022) & (K Units)
Table 37. Global Poliovirus Vaccine Inactivated Sales by Application (2023-2028) & (K Units)
Table 38. Global Poliovirus Vaccine Inactivated Revenue by Application (2017-2022) & (USD Million)
Table 39. Global Poliovirus Vaccine Inactivated Revenue by Application (2023-2028) & (USD Million)
Table 40. Global Poliovirus Vaccine Inactivated Price by Application (2017-2022) & (USD/Unit)
Table 41. Global Poliovirus Vaccine Inactivated Price by Application (2023-2028) & (USD/Unit)
Table 42. North America Poliovirus Vaccine Inactivated Sales by Country (2017-2022) & (K Units)
Table 43. North America Poliovirus Vaccine Inactivated Sales by Country (2023-2028) & (K Units)
Table 44. North America Poliovirus Vaccine Inactivated Revenue by Country (2017-2022) & (USD Million)
Table 45. North America Poliovirus Vaccine Inactivated Revenue by Country (2023-2028) & (USD Million)
Table 46. North America Poliovirus Vaccine Inactivated Sales by Type (2017-2022) & (K Units)
Table 47. North America Poliovirus Vaccine Inactivated Sales by Type (2023-2028) & (K Units)
Table 48. North America Poliovirus Vaccine Inactivated Sales by Application (2017-2022) & (K Units)
Table 49. North America Poliovirus Vaccine Inactivated Sales by Application (2023-2028) & (K Units)
Table 50. Europe Poliovirus Vaccine Inactivated Sales by Country (2017-2022) & (K Units)
Table 51. Europe Poliovirus Vaccine Inactivated Sales by Country (2023-2028) & (K Units)
Table 52. Europe Poliovirus Vaccine Inactivated Revenue by Country (2017-2022) & (USD Million)
Table 53. Europe Poliovirus Vaccine Inactivated Revenue by Country (2023-2028) & (USD Million)
Table 54. Europe Poliovirus Vaccine Inactivated Sales by Type (2017-2022) & (K Units)
Table 55. Europe Poliovirus Vaccine Inactivated Sales by Type (2023-2028) & (K Units)
Table 56. Europe Poliovirus Vaccine Inactivated Sales by Application (2017-2022) & (K Units)
Table 57. Europe Poliovirus Vaccine Inactivated Sales by Application (2023-2028) & (K Units)
Table 58. Asia-Pacific Poliovirus Vaccine Inactivated Sales by Region (2017-2022) & (K Units)
Table 59. Asia-Pacific Poliovirus Vaccine Inactivated Sales by Region (2023-2028) & (K Units)
Table 60. Asia-Pacific Poliovirus Vaccine Inactivated Revenue by Region (2017-2022) & (USD Million)
Table 61. Asia-Pacific Poliovirus Vaccine Inactivated Revenue by Region (2023-2028) & (USD Million)
Table 62. Asia-Pacific Poliovirus Vaccine Inactivated Sales by Type (2017-2022) & (K Units)
Table 63. Asia-Pacific Poliovirus Vaccine Inactivated Sales by Type (2023-2028) & (K Units)
Table 64. Asia-Pacific Poliovirus Vaccine Inactivated Sales by Application (2017-2022) & (K Units)
Table 65. Asia-Pacific Poliovirus Vaccine Inactivated Sales by Application (2023-2028) & (K Units)
Table 66. South America Poliovirus Vaccine Inactivated Sales by Country (2017-2022) & (K Units)
Table 67. South America Poliovirus Vaccine Inactivated Sales by Country (2023-2028) & (K Units)
Table 68. South America Poliovirus Vaccine Inactivated Revenue by Country (2017-2022) & (USD Million)
Table 69. South America Poliovirus Vaccine Inactivated Revenue by Country (2023-2028) & (USD Million)
Table 70. South America Poliovirus Vaccine Inactivated Sales by Type (2017-2022) & (K Units)
Table 71. South America Poliovirus Vaccine Inactivated Sales by Type (2023-2028) & (K Units)
Table 72. South America Poliovirus Vaccine Inactivated Sales by Application (2017-2022) & (K Units)
Table 73. South America Poliovirus Vaccine Inactivated Sales by Application (2023-2028) & (K Units)
Table 74. Middle East & Africa Poliovirus Vaccine Inactivated Sales by Region (2017-2022) & (K Units)
Table 75. Middle East & Africa Poliovirus Vaccine Inactivated Sales by Region (2023-2028) & (K Units)
Table 76. Middle East & Africa Poliovirus Vaccine Inactivated Revenue by Region (2017-2022) & (USD Million)
Table 77. Middle East & Africa Poliovirus Vaccine Inactivated Revenue by Region (2023-2028) & (USD Million)
Table 78. Middle East & Africa Poliovirus Vaccine Inactivated Sales by Type (2017-2022) & (K Units)
Table 79. Middle East & Africa Poliovirus Vaccine Inactivated Sales by Type (2023-2028) & (K Units)
Table 80. Middle East & Africa Poliovirus Vaccine Inactivated Sales by Application (2017-2022) & (K Units)
Table 81. Middle East & Africa Poliovirus Vaccine Inactivated Sales by Application (2023-2028) & (K Units)
Table 82. Poliovirus Vaccine Inactivated Raw Material
Table 83. Key Manufacturers of Poliovirus Vaccine Inactivated Raw Materials
Table 84. Direct Channel Pros & Cons
Table 85. Indirect Channel Pros & Cons
Table 86. Poliovirus Vaccine Inactivated Typical Distributors
Table 87. Poliovirus Vaccine Inactivated Typical Customers
List of Figures
Figure 1. Poliovirus Vaccine Inactivated Picture
Figure 2. Global Poliovirus Vaccine Inactivated Revenue Market Share by Type in 2021
Figure 3. Human Diploid Cell
Figure 4. Monkey Kidney Cell
Figure 5. Global Poliovirus Vaccine Inactivated Revenue Market Share by Application in 2021
Figure 6. Public
Figure 7. Private
Figure 8. Global Poliovirus Vaccine Inactivated Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Poliovirus Vaccine Inactivated Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Poliovirus Vaccine Inactivated Sales (2017-2028) & (K Units)
Figure 11. Global Poliovirus Vaccine Inactivated Price (2017-2028) & (USD/Unit)
Figure 12. Global Poliovirus Vaccine Inactivated Production Capacity (2017-2028) & (K Units)
Figure 13. Global Poliovirus Vaccine Inactivated Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Poliovirus Vaccine Inactivated Market Drivers
Figure 15. Poliovirus Vaccine Inactivated Market Restraints
Figure 16. Poliovirus Vaccine Inactivated Market Trends
Figure 17. Global Poliovirus Vaccine Inactivated Sales Market Share by Manufacturer in 2021
Figure 18. Global Poliovirus Vaccine Inactivated Revenue Market Share by Manufacturer in 2021
Figure 19. Poliovirus Vaccine Inactivated Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Poliovirus Vaccine Inactivated Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Poliovirus Vaccine Inactivated Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Poliovirus Vaccine Inactivated Sales Market Share by Region (2017-2028)
Figure 23. Global Poliovirus Vaccine Inactivated Revenue Market Share by Region (2017-2028)
Figure 24. North America Poliovirus Vaccine Inactivated Revenue (2017-2028) & (USD Million)
Figure 25. Europe Poliovirus Vaccine Inactivated Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Poliovirus Vaccine Inactivated Revenue (2017-2028) & (USD Million)
Figure 27. South America Poliovirus Vaccine Inactivated Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Poliovirus Vaccine Inactivated Revenue (2017-2028) & (USD Million)
Figure 29. Global Poliovirus Vaccine Inactivated Sales Market Share by Type (2017-2028)
Figure 30. Global Poliovirus Vaccine Inactivated Revenue Market Share by Type (2017-2028)
Figure 31. Global Poliovirus Vaccine Inactivated Price by Type (2017-2028) & (USD/Unit)
Figure 32. Global Poliovirus Vaccine Inactivated Sales Market Share by Application (2017-2028)
Figure 33. Global Poliovirus Vaccine Inactivated Revenue Market Share by Application (2017-2028)
Figure 34. Global Poliovirus Vaccine Inactivated Price by Application (2017-2028) & (USD/Unit)
Figure 35. North America Poliovirus Vaccine Inactivated Sales Market Share by Type (2017-2028)
Figure 36. North America Poliovirus Vaccine Inactivated Sales Market Share by Application (2017-2028)
Figure 37. North America Poliovirus Vaccine Inactivated Sales Market Share by Country (2017-2028)
Figure 38. North America Poliovirus Vaccine Inactivated Revenue Market Share by Country (2017-2028)
Figure 39. United States Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Poliovirus Vaccine Inactivated Sales Market Share by Type (2017-2028)
Figure 43. Europe Poliovirus Vaccine Inactivated Sales Market Share by Application (2017-2028)
Figure 44. Europe Poliovirus Vaccine Inactivated Sales Market Share by Country (2017-2028)
Figure 45. Europe Poliovirus Vaccine Inactivated Revenue Market Share by Country (2017-2028)
Figure 46. Germany Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Poliovirus Vaccine Inactivated Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Poliovirus Vaccine Inactivated Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Poliovirus Vaccine Inactivated Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Poliovirus Vaccine Inactivated Revenue Market Share by Region (2017-2028)
Figure 55. China Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Poliovirus Vaccine Inactivated Sales Market Share by Type (2017-2028)
Figure 62. South America Poliovirus Vaccine Inactivated Sales Market Share by Application (2017-2028)
Figure 63. South America Poliovirus Vaccine Inactivated Sales Market Share by Country (2017-2028)
Figure 64. South America Poliovirus Vaccine Inactivated Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Poliovirus Vaccine Inactivated Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Poliovirus Vaccine Inactivated Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Poliovirus Vaccine Inactivated Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Poliovirus Vaccine Inactivated Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Poliovirus Vaccine Inactivated Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Poliovirus Vaccine Inactivated in 2021
Figure 76. Manufacturing Process Analysis of Poliovirus Vaccine Inactivated
Figure 77. Poliovirus Vaccine Inactivated Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source
| 【不活化ポリオウイルスワクチンについて】 不活化ポリオウイルスワクチン（IPV）は、ポリオウイルスによって引き起こされる疾患、すなわち小児麻痺（ポリオ）を予防するためのワクチンです。このワクチンは、病原性を持たない形に処理されたウイルスを含んでおり、投与によって免疫反応を誘導します。本稿では、IPVの定義、特徴、種類、用途、関連技術について詳述します。 IPVの定義としては、ポリオウイルスの不活化株を含むワクチンとされます。このワクチンは、ウイルスの病原性を取り除くための物理的または化学的な方法によって不活化されており、これによってワクチン接種者はポリオウイルスによる感染を防ぐための免疫を獲得することができます。不活化されているため、接種後に実際の感染を引き起こすことはありません。 特徴としては、IPVは注射によって投与されることが挙げられます。一般的には、筋肉内注射で行われ、通常、上腕部または大腿部への接種が推奨されます。このワクチンは、非常に高い安全性を持っているため、妊娠中の女性や免疫力が低下している人々、慢性的な病気を持つ人々でも接種が可能です。さらに、IPVは飲み薬の形で投与される経口ポリオワクチン（OPV）に比べて、ワクチン接種後にウイルスが体内に排出されるリスクが低く、ウイルスの拡散を防ぐことができる重要な要素です。 IPVは主に二種類に分類されます。一つは、サバインタイプの不活化ワクチンで、もう一つは、スボタイプの不活化ワクチンです。サバインタイプは、通常のポリオウイルスに基づいており、ウイルスの全株が含まれています。一方、スボタイプは、特定の変異株を以って構成されています。これらのワクチンはそれぞれ異なる免疫反応を引き起こし、一部の国や地域では、複数のタイプを組み合わせて使用することがあります。 IPVの用途は、主にポリオの予防です。ポリオは、特に5歳未満の小児において深刻な神経系の障害を引き起こす可能性があります。重症の場合、呼吸筋の麻痺や四肢の麻痺を引き起こし、生命を脅かすことにも繋がります。そのため、ワクチン接種を通じて子供たちを保護することは非常に重要であり、多くの国で定期予防接種スケジュールに組み込まれています。 また、IPVは国際的な公衆衛生の観点からも重要です。ポリオ疫病の根絶に向けた努力の一環として、世界保健機関（WHO）は、すべての国でIPVの導入を推奨しています。特に、ポリオがあった地域でのワクチン接種率の向上は、ウイルスの再流行を防ぐために非常に重要です。IPVは、特に高リスク地域において、ポリオウイルスの感染拡大を防止し、地域社会の保健安定性を向上させるための基盤となります。 さらに、IPVの開発に関連する技術も多岐にわたります。不活化方法には、フォルムアルデヒドやベータプロピオラクトン（BPL）、超音波照射などの化学物質が用いられることがあります。これらの方法によって、ウイルスの病原性が完全に消失すると同時に、ワクチンの免疫原性を保つことが可能です。また、モダンなバイオテクノロジーの進展に伴い、遺伝子組換え技術を用いてウイルスエピトープを合成し、その結果として新たな形のワクチン開発が進められています。 最後に、IPVはその安全性や効果から、多くの国で広く使用されていますが、一方でOPVとの併用や選択についてはさまざまな議論があります。OPVは経口投与が可能で、集団免疫を高める効果がありますが、稀なケースではワクチン由来のポリオウイルスが感染を引き起こすことがあります。このため、慎重な選択が求められています。 不活化ポリオウイルスワクチンは、ポリオウイルスによる感染症を防ぐために不可欠なツールであり、今後もその重要性は変わらないでしょう。公衆衛生の観点からも、ワクチン接種の普及と啓発に向けた努力が必要であり、人々がこの疾患から守られるようにするための取り組みが続けられていきます。IPVのさらなる研究と革新が、将来的なポリオの根絶に向けた道を開くことを期待しています。 |